Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial. - Wikidata - awgldk - TriplyDB

Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

http://www.wikidata.org/entity/Q33806121

about

The cancer theory of pulmonary arterial hypertension.Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases.Autophagy and inflammation in chronic respiratory disease.Emerging Therapeutics in Pulmonary Hypertension.Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs.Immune regulation of systemic hypertension, pulmonary arterial hypertension, and preeclampsia: shared disease mechanisms and translational opportunities.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus

P2860

Q33788493-02F066C1-F9DF-4F61-9A21-85699F24C2A8 Q36996364-2B3DAF77-EE34-40CE-B738-B11D32D2DD62 Q37649641-203F517A-774C-403D-8155-33D204BB8836 Q47663797-278378CE-8E50-4FB6-BC01-E40830C7E2AC Q47700134-385C0EED-DB8C-4BDE-91F4-84F488D78BAD Q48035289-46A0113B-64E9-4B93-9A62-1D2E2196BA50 Q49471057-A3CBE616-70F4-4D67-9FF6-FEF31DDCCD2F Q49600503-A2595DC4-EFB0-4FA9-B196-6551EEBC7881 Q56035477-8A9C4D2D-6296-41E4-A653-55EE6E7007DA

P2860

Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.

http://www.wikidata.org/entity/Q33806121

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Everolimus in patients with se ...... fety and efficacy pilot trial.

@ast

Everolimus in patients with se ...... fety and efficacy pilot trial.

@en

type

label

Everolimus in patients with se ...... fety and efficacy pilot trial.

@ast

Everolimus in patients with se ...... fety and efficacy pilot trial.

@en

prefLabel

Everolimus in patients with se ...... fety and efficacy pilot trial.

@ast

Everolimus in patients with se ...... fety and efficacy pilot trial.

@en

P1433

Q33806121-2D590230-C27C-49CC-A74C-4F3A8F283A82

P1476

Q33806121-392BC165-7AD6-4392-9FF3-977E4D3AA468

P2093

Q33806121-B6BC4370-6A68-4077-9547-0EDE268283AD

Q33806121-D658D434-EBA6-4163-AED5-2111A97A51CA

Q33806121-DAFC8067-6FA1-4268-974B-40138A643275

Q33806121-E5F7E44C-B0D8-453C-A18D-A83D845EFE4E

Q33806121-F9E60AF1-19CE-4230-8F82-62A21FE00BC6

P2860

Q33806121-11E563B7-A2C2-49F1-BB35-75AA57A719A2

Q33806121-170C5371-8EA3-4A73-864E-F8D6805FEE3A

Q33806121-376A4604-D7A2-4C32-AD41-8B3B589A6E42

Q33806121-48C11371-7F8A-4873-9CC5-65CDED304D37

Q33806121-4DC50D95-2117-49A8-BEA2-EC2CC9887E71

Q33806121-80B9F61E-DAB0-4F99-86B7-D5933834D467

Q33806121-8C50D5AC-94FB-4756-A58B-846BF5899828

Q33806121-A48664FC-DA03-4CB9-A700-6BE5B605E9DE

Q33806121-A56DAD83-097A-4472-8DD9-A65AC8BB1782

Q33806121-AFF66692-34B6-4487-A94C-6DEBB897F330

P304

Q33806121-7D5CDD12-7B7A-4969-A35F-613B2E77A26B

P31

Q33806121-1410C818-506D-475C-9780-A8AB1DA41284

P356

Q33806121-0C3FFF70-B462-4ED7-B8F9-B84FE4EBE019

P433

Q33806121-E6521BC4-0968-47B4-B6A2-247C264632A9

P478

Q33806121-38B19F55-8908-486D-961A-CC3AEFFE1E02

P577

Q33806121-D0B5C27F-E59B-42B0-B437-E99F4BC366BB

P5875

Q33806121-6313785E-B6D6-4153-B747-B40407F17342

P698

Q33806121-07D2CE0D-2149-428E-A833-0D6F305D2654

P932

Q33806121-C9D5962E-2109-4CDE-B41A-1E1A714BD52F

P356

P1433

Pulmonary circulation

P1476

Everolimus in patients with se ...... fety and efficacy pilot trial.

@en

P2093

Hans-Jürgen Seyfarth

http://www.w3.org/2001/XMLSchema#string

Hubert R Wirtz

http://www.w3.org/2001/XMLSchema#string

Michael Halank

http://www.w3.org/2001/XMLSchema#string

Petra Neuhaus

http://www.w3.org/2001/XMLSchema#string

Stefan Hammerschmidt

http://www.w3.org/2001/XMLSchema#string

P2860

40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats.

Systemic sclerosis-associated pulmonary arterial hypertension

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.

Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.

P304

632-638

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/674311

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260717433

http://www.w3.org/2001/XMLSchema#string

P698

24618547

http://www.w3.org/2001/XMLSchema#string

P932

4070806

http://www.w3.org/2001/XMLSchema#string